Aclaris Therapts (ACRS) Stock Price, Quote & News - Mboum

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

galaxy_celebrity Sep. 14 at 2:45 PM

$ACRS me down %20 this guy still pumping hope for the people ???? Still 16% to go and then I have my breakeven ..... What about lost of 1 month ??.. Time is money 💰🤑

0 · Reply

Acan1219 Sep. 14 at 1:55 PM

$ACRS Let’s Goooo my Real Bull’s!!

0 · Reply

Acan1219 Sep. 14 at 1:53 PM

$ACRS Where’s Galaxy???? Scared little guy.. Did I post on Friday we move up!!! Stop Bashing and learn the game if that’s even possible for you!!

0 · Reply

Ineverlose7 Sep. 14 at 9:00 AM

$ACRS no fake pumpers here bud, just genuinely hope that the new drugs works, helps people and the company / stock gets the recognition it deserves with the price.

0 · Reply

galaxy_celebrity Sep. 13 at 11:25 PM

$ACRS I WOULD NOT INVEST HERE / FAKE PUMPERS

0 · Reply

galaxy_celebrity Sep. 13 at 9:54 PM

0 · Reply

galaxy_celebrity Sep. 13 at 5:46 PM

$ACRS 😄😄

0 · Reply

Acan1219 Sep. 12 at 1:39 AM

$ACRS Some of you guys just don’t get it! Almost every Biotech I looked up was down for days! The exact same pullback on all of them some a little more some a little less but all down! If you can’t stomach the swings you shouldn’t be here! Next week we rise up! Again ACRS will be Double Digits soon enough Imho..

2 · Reply

galaxy_celebrity Sep. 11 at 4:46 PM

$ACRS where are the FAKE PUMPERS here ?? We dont here them nowadays?? This POS dropped down from 6.50 level to 5.20 in 7 days !!!! Does the picture says anything to all of us as a loyal share holder ?

1 · Reply

galaxy_celebrity Sep. 11 at 4:34 PM

$ACRS NASTY STOCK !!!

0 · Reply

Latest News on ACRS

Aclaris Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2026, 2:45 PM EDT - 3 days ago

Aclaris Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Sep 3, 2026, 8:00 AM EDT - 11 days ago

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aclaris Therapeutics initiated with a Buy at Canaccord

2026-09-01T10:25:55.000Z - 13 days ago

Aclaris Therapeutics initiated with a Buy at Canaccord

Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib

2026-08-06T21:30:34.000Z - 5 weeks ago

Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib

Aclaris Therapeutics files automatic mixed securities shelf

2026-08-06T21:10:31.000Z - 5 weeks ago

Aclaris Therapeutics files automatic mixed securities shelf

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aug 6, 2026, 4:35 PM EDT - 5 weeks ago

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c)

2026-08-06T11:53:11.000Z - 5 weeks ago

Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c)

Aclaris Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Aclaris Therapeutics Earnings release: Q2 2026

Aclaris Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Aclaris Therapeutics Quarterly report: Q2 2026

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aug 6, 2026, 6:59 AM EDT - 5 weeks ago

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics management to meet with Oppenheimer

2026-06-16T18:40:11.000Z - 2 months ago

Aclaris Therapeutics management to meet with Oppenheimer

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 2:00 PM EDT - 3 months ago

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Aclaris Therapeutics Transcript: AGM 2026

Jun 4, 2026, 9:00 AM EDT - 3 months ago

Aclaris Therapeutics Transcript: AGM 2026

Aclaris Therapeutics initiated with an Outperform at LifeSci Capital

2026-06-02T00:35:11.000Z - 3 months ago

Aclaris Therapeutics initiated with an Outperform at LifeSci Capital

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 8:30 AM EDT - 3 months ago

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 14, 2026, 12:35 PM EDT - 4 months ago

Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Aclaris Therapeutics Slides: FY 2026

May 14, 2026, 12:35 PM EDT - 4 months ago

Aclaris Therapeutics Slides: FY 2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

May 8, 2026, 8:30 AM EDT - 4 months ago

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

2026-05-07T15:19:50.000Z - 4 months ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

2026-05-07T13:36:55.000Z - 4 months ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

Aclaris Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Aclaris Therapeutics Earnings release: Q1 2026

Aclaris Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Aclaris Therapeutics Quarterly report: Q1 2026

Aclaris Therapeutics Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Aclaris Therapeutics Slides: Corporate presentation

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

May 7, 2026, 6:59 AM EDT - 4 months ago

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

2026-05-05T10:58:43.000Z - 4 months ago

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-05-05T08:30:14.000Z - 4 months ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-05-04T20:40:03.000Z - 4 months ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

2026-04-29T12:21:19.000Z - 4 months ago

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

Aclaris Therapeutics Transcript: Study update

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Aclaris Therapeutics Transcript: Study update

Aclaris Therapeutics Press release: Study update

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Aclaris Therapeutics Press release: Study update

Aclaris Therapeutics Slides: Study update

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Aclaris Therapeutics Slides: Study update

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

2026-04-28T11:21:27.000Z - 4 months ago

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Apr 28, 2026, 6:30 AM EDT - 4 months ago

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Apr 27, 2026, 4:45 PM EDT - 4 months ago

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics management to meet virtually with Craig-Hallum

2026-04-27T15:45:50.000Z - 4 months ago

Aclaris Therapeutics management to meet virtually with Craig-Hallum

Aclaris Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Aclaris Therapeutics Proxy statement: Proxy filing

Aclaris Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Aclaris Therapeutics Proxy statement: Proxy filing

Aclaris Therapeutics initiated with an Outperform at Oppenheimer

2026-04-16T11:01:43.000Z - 5 months ago

Aclaris Therapeutics initiated with an Outperform at Oppenheimer

Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 14, 2026, 12:00 PM EDT - 5 months ago

Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 8, 2026, 8:30 AM EDT - 5 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Mar 27, 2026, 10:10 AM EDT - 5 months ago

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 20, 2026, 11:00 AM EDT - 5 months ago

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug

2026-03-18T11:18:06.000Z - 6 months ago

Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Mar 18, 2026, 6:55 AM EDT - 6 months ago

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:40 PM EDT - 6 months ago

Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Aclaris Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 8:40 AM EST - 6 months ago

Aclaris Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

2026-02-26T12:39:16.000Z - 6 months ago

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

Aclaris Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Aclaris Therapeutics Annual report: Q4 2025

Aclaris Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Aclaris Therapeutics Earnings release: Q4 2025

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:58 AM EST - 6 months ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Feb 24, 2026, 7:00 AM EST - 6 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Aclaris Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 2:30 PM EST - 7 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Jan 27, 2026, 6:55 AM EST - 7 months ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Jan 12, 2026, 6:55 AM EST - 8 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Aclaris Therapeutics Transcript: Study Result

Aclaris Therapeutics Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Aclaris Therapeutics Press release: Study Result

Aclaris Therapeutics Slides: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Aclaris Therapeutics Slides: Study Result

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Jan 6, 2026, 6:59 AM EST - 8 months ago

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Dec 19, 2025, 4:01 PM EST - 8 months ago

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Aclaris Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 11:00 AM EST - 9 months ago

Aclaris Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 9:00 AM EST - 10 months ago

Aclaris Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Aclaris Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 1:20 PM EST - 10 months ago

Aclaris Therapeutics Transcript: Stifel 2025 Healthcare Conference

Aclaris Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:00 AM EST - 10 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Aclaris Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 10 months ago

Aclaris Therapeutics Slides: Corporate Presentation

Aclaris Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Aclaris Therapeutics Quarterly report: Q3 2025

Aclaris Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Aclaris Therapeutics Earnings release: Q3 2025

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 6:59 AM EST - 10 months ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics Transcript: R&D Day 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Aclaris Therapeutics Transcript: R&D Day 2025

Aclaris Therapeutics Slides: FY 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Aclaris Therapeutics Slides: FY 2025

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 9:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Sep 9, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 27, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Quarterly report: Q2 2025

Aclaris Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Earnings release: Q2 2025

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:59 AM EDT - 1 year ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Transcript: Status Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Status Update

Aclaris Therapeutics Press release: Status Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Press release: Status Update

Aclaris Therapeutics Slides: Status Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Slides: Status Update

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Leadership Transition

Jul 28, 2025, 8:45 AM EDT - 1 year ago

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Jun 30, 2025, 11:30 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Aclaris Therapeutics Slides: FY 2025

Jun 30, 2025, 11:30 AM EDT - 1 year ago

Aclaris Therapeutics Slides: FY 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 30, 2025, 9:31 AM EDT - 1 year ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 26, 2025, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 23, 2025, 6:59 AM EDT - 1 year ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 1:20 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 10:30 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 28, 2025, 9:20 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 9, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Quarterly report: Q1 2025

Aclaris Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Earnings release: Q1 2025

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:50 AM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Aclaris Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Mar 4, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Aclaris Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Annual report: Q4 2024

Aclaris Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q4 2024

Aclaris Therapeutics Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Feb 12, 2025, 6:50 AM EST - 1 year ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 30, 2025, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Registration statement: Registration Filing

Dec 19, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

Aclaris Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:00 PM EST - 1 year ago

Aclaris Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Transcript: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Transcript: Status Update

Aclaris Therapeutics Press release: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Press release: Status Update

Aclaris Therapeutics Slides: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Slides: Status Update

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Quarterly report: Q3 2024

Aclaris Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q3 2024

Aclaris Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Quarterly report: Q2 2024

Aclaris Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Earnings release: Q2 2024

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 16, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 25, 2024, 12:36 PM EDT - 2 years ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Aclaris Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 11:20 AM EDT - 2 years ago

Aclaris Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 8, 2024, 6:30 AM EDT - 2 years ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

Aclaris Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings Call Transcript: Q1 2024

Aclaris Therapeutics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Quarterly report: Q1 2024

Aclaris Therapeutics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings release: Q1 2024

Aclaris Therapeutics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Slides: Q1 2024

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

galaxy_celebrity Sep. 14 at 2:45 PM

$ACRS me down %20 this guy still pumping hope for the people ???? Still 16% to go and then I have my breakeven ..... What about lost of 1 month ??.. Time is money 💰🤑

0 · Reply

Acan1219 Sep. 14 at 1:55 PM

$ACRS Let’s Goooo my Real Bull’s!!

0 · Reply

Acan1219 Sep. 14 at 1:53 PM

$ACRS Where’s Galaxy???? Scared little guy.. Did I post on Friday we move up!!! Stop Bashing and learn the game if that’s even possible for you!!

0 · Reply

Ineverlose7 Sep. 14 at 9:00 AM

$ACRS no fake pumpers here bud, just genuinely hope that the new drugs works, helps people and the company / stock gets the recognition it deserves with the price.

0 · Reply

galaxy_celebrity Sep. 13 at 11:25 PM

$ACRS I WOULD NOT INVEST HERE / FAKE PUMPERS

0 · Reply

galaxy_celebrity Sep. 13 at 9:54 PM

0 · Reply

galaxy_celebrity Sep. 13 at 5:46 PM

$ACRS 😄😄

0 · Reply

Acan1219 Sep. 12 at 1:39 AM

$ACRS Some of you guys just don’t get it! Almost every Biotech I looked up was down for days! The exact same pullback on all of them some a little more some a little less but all down! If you can’t stomach the swings you shouldn’t be here! Next week we rise up! Again ACRS will be Double Digits soon enough Imho..

2 · Reply

galaxy_celebrity Sep. 11 at 4:46 PM

$ACRS where are the FAKE PUMPERS here ?? We dont here them nowadays?? This POS dropped down from 6.50 level to 5.20 in 7 days !!!! Does the picture says anything to all of us as a loyal share holder ?

1 · Reply

galaxy_celebrity Sep. 11 at 4:34 PM

$ACRS NASTY STOCK !!!

0 · Reply

Jellysquid1 Sep. 11 at 4:21 PM

$ACRS What happened At Cantors presentation Yesterday that caused This drop?

1 · Reply

galaxy_celebrity Sep. 11 at 3:49 PM

$ACRS STILL BLEEDING LIKE HELL and it is hurting lots of real disappointed investors !!!

0 · Reply

outlawinvestor1 Sep. 10 at 6:53 PM

$ACRS imminent ati-052 (tslpxil4ra) asthma and ad data first followed by bosakitug (tslp mono) ad data 6 weeks later. this is an optimal sequencing approach for the programs. i think the bosakitug ad trial will likely fail, but the ati-052 has a good chance for success.

1 · Reply

galaxy_celebrity Sep. 10 at 1:49 PM

$ACRS real nasty POS !!! so painfull to lose so much in 10 days time ! Thought was a decent stock to invest in but so bloody fragile 🤮

1 · Reply

Jellysquid1 Sep. 10 at 1:41 AM

$ACRS Interesting Back To back Lineup Tomorrow ! At Cantor Global Healthcare Conference CRVS At 1:00PM ACRS At 2:45 PM

1 · Reply

buymoremakemore Sep. 9 at 8:47 PM

$ACRS this likely explains the selloff today. Sanofi’s data readout shouldnt have had this much of an effect. Recovery soon. Maybe Sanofi’s data can inform ATI-052 phase 1b trial. https://x.com/semodough/status/2097310763845095513?s=46

0 · Reply

Banana0815 Sep. 9 at 7:04 PM

$ACRS whats happening??

1 · Reply

Vladxccc Sep. 9 at 6:47 PM

$ACRS my stomach hurts

0 · Reply

Banana0815 Sep. 8 at 1:26 PM

$ACRS why am i watching at 5.50$ premarket?

1 · Reply

Cheesyisi Sep. 3 at 1:26 PM

0 · Reply

focafoca99 Sep. 3 at 12:26 PM

$ACRS conference appearance is set for Sept. 10, with CEO Neal Walker in a Cantor Global Healthcare Conference fireside chat.

0 · Reply

layLOW120 Sep. 3 at 4:17 AM

$ACRS break 6.60, Pts 7 and then off to 8.30s, break 11 then gap to 12.

0 · Reply